Head-to-head · WeighScore
Remi Meds vs Wisp
The verdict
Wisp takes it — 64.4/100 to 48.4/100.
Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Remi Meds | Wisp |
|---|---|---|
| WeighScore | 48.4/100 | 64.4/100 |
| Grade | C | C |
| Scorecard rank | #493 | #243 |
| Semaglutide | $249/mo (0.25 mg dose, compounded) | $225/mo (compounded oral) |
| Tirzepatide | $349/mo (2.25 mg dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #493 · C
Strengths
- Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
- LegitScript verification badge on the homepage
- Publishes 503A FDCA compliance language on the tirzepatide page
- Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
- Operating corporate entity disclosed (T-C Health Co)
Where it loses points
- No named medical director, founder, or physician on any public page
- States served not listed — 'nationwide' claim with no per-state detail
- Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
- Year founded and corporate history are opaque
- Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure
Graded #243 · C
Strengths
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
Where it loses points
- The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
- The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
- Brand-name access is a prescription, not a dispensed product, so the drug cost is outside anything quoted here
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.